Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 25 for:    clopidogrel | South Dakota, United States
Previous Study | Return to List | Next Study

Pharmacogenomics and Effective Treatment With Clopidogrel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01611545
Recruitment Status : Completed
First Posted : June 5, 2012
Last Update Posted : June 11, 2015
Sponsor:
Collaborators:
Avera Heart Hospital of South Dakota
North Central Heart Institute
Information provided by (Responsible Party):
Avera McKennan Hospital & University Health Center

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Condition or disease Intervention/treatment
Pharmacogenomics and Cardiovascular Events Genetic: Pharmacogenomics

Detailed Description:
The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.
Study Start Date : June 2012
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Clopidogrel
Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
 Genetic: Pharmacogenomics
Utilizing pharmacogenomics to determine the most effective treatment
Other Name: Plavix


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Biospecimen Retention:   Samples With DNA
blood or buccal samples

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients of either the Avera Heart Hospital of South Dakota or North Central Heart Institute who have been precribed Clopidogrel or are being considered for treatment with Clopidogrel.
Criteria

Inclusion Criteria:

  • Currently taking or prescribed Clopidogrel or under consideration
  • Acute/interventionPatients of the Avera Heart Hospital
  • Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute

Exclusion Criteria:

  • Unable to provide informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01611545


Locations
Layout table for location information
United States, South Dakota
Avera Institute for Human Genetics
Sioux Falls, South Dakota, United States, 57108
Sponsors and Collaborators
Avera McKennan Hospital & University Health Center
Avera Heart Hospital of South Dakota
North Central Heart Institute
Investigators
Layout table for investigator information
Principal Investigator: Gareth Davies, PhD Avera McKennan Hospital & University Health Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Layout table for additonal information
Responsible Party: Avera McKennan Hospital & University Health Center
ClinicalTrials.gov Identifier: NCT01611545    
Other Study ID Numbers: AIHG-1410-Clopidogrel
First Posted: June 5, 2012    Key Record Dates
Last Update Posted: June 11, 2015
Last Verified: June 2015
Keywords provided by Avera McKennan Hospital & University Health Center:
Pharmacogenomics
Pharmacogenetics
Clopidogrel
Plavix